# Effectiveness of CRD-740 in Heart Failure

> **NCT05409183** · PHASE2 · TERMINATED · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Heart Failure
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
- Cardiovascular Diseases
- Heart Diseases

## Interventions

- **DRUG:** CRD-740
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05409183
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-26
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-07-25
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Part A of the study was successfully concluded. Part B of the study was not conducted in favor of redesigned new studies.
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05409183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05409183, "Effectiveness of CRD-740 in Heart Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05409183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*